VWA
PACB icon

V Wealth Advisors’s Pacific Biosciences PACB Stock Holding History

V Wealth Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,102
Closed -$227K – 466
2021
Q4 		$227K Buy
+11,102
New +$268K 0.03% 414

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

V Wealth Advisors's PACB Position: Q1 2022 in Review

V Wealth Advisors sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 11,102 shares — an estimated $227K sold.

V Wealth Advisors first reported a position in PACB in Q4 2021 and held it in 1 quarter. The position peaked at $227K in Q4 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

  • V Wealth Advisors reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
  • V Wealth Advisors sold 11,102 Pacific Biosciences shares in Q1 2022, an estimated $227K.
  • V Wealth Advisors first reported a position in Pacific Biosciences in Q4 2021 and held it in 1 quarter.
  • V Wealth Advisors's Pacific Biosciences position peaked at $227K in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on V Wealth Advisors's 13F filing for Q1 2022, filed 16 May 2022.